Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Avacta Group plc ( (GB:AVCT) ) just unveiled an announcement.
Avacta Group plc has appointed Panmure Liberum Limited as a joint broker alongside Peel Hunt, enhancing its financial advisement team. This strategic move is expected to strengthen Avacta’s market presence and support its ongoing efforts in expanding innovative cancer therapies through its pre|CISION® platform.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) to target cancer therapies. Utilizing its proprietary pre|CISION® platform, Avacta seeks to deliver highly potent drug payloads specifically to tumor sites, offering advantages over traditional therapies.
YTD Price Performance: -5.00%
Average Trading Volume: 1,342,520
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £177.1M
Learn more about AVCT stock on TipRanks’ Stock Analysis page.
